

EAGLE PHARMACEUTICALS, INC.

Form 3

February 11, 2014

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â Krill Steven L.
 (Last) (First) (Middle)

2. Date of Event Requiring Statement

(Month/Day/Year)
 02/11/2014

3. Issuer Name and Ticker or Trading Symbol

EAGLE PHARMACEUTICALS, INC. [EGRX]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

___ Director ___ 10% Owner

Officer ___ Other

(give title below) (specify below)

Chief Scientific Officer

6. Individual or Joint/Group

Filing(Check Applicable Line)

Form filed by One Reporting Person

___ Form filed by More than One Reporting Person

C/O EAGLE
 PHARMACEUTICALS,
 INC.,Â 50 TICE BLVD., SUITE
 315

(Street)

WOODCLIFF
 LAKE,Â NJÂ 07677

(City) (State) (Zip)

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
 (Instr. 4)

2. Amount of Securities Beneficially Owned
 (Instr. 4)

3. Ownership Form:
 Direct (D)
 or Indirect (I)
 (Instr. 5)

4. Nature of Indirect Beneficial Ownership
 (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
 (Instr. 4)

2. Date Exercisable and Expiration Date
 (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security
 (Instr. 4)

4. Conversion or Exercise Price of Derivative

5. Ownership Form of Derivative Security:

6. Nature of Indirect Beneficial Ownership
 (Instr. 5)

Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (right to buy)	Â (1)	09/25/2021	Common Stock	7,800	\$ 8.78	D	Â
Stock Option (right to buy)	Â (2)	07/11/2022	Common Stock	5,460	\$ 8.78	D	Â
Stock Option (right to buy)	Â (3)	04/18/2023	Common Stock	21,917	\$ 4.42	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Krill Steven L. C/O EAGLE PHARMACEUTICALS, INC. 50 TICE BLVD., SUITE 315 WOODCLIFF LAKE, NJ 07677	Â	Â	Â Chief Scientific Officer	Â

Signatures

/s/ Scott Tarriff,
Attorney-In-Fact

02/11/2014

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25% of the shares subject to the option vest on October 26, 2012 and the remainder shall vest in equal monthly installments over a period of three years.
- (2) 25% of the shares subject to the option vest on July 12, 2013 and the remainder shall vest in equal monthly installments over a period of three years.
- (3) 25% of the shares subject to the option vest on April 19, 2014 and the remainder shall vest in equal monthly installments over a period of three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.